Taking into account previous reports that IGF1R pathway is a potential therapeutic target for MPNST patients, and the cross-talk between IGF1R and EGFR signaling pathways was detected in other types of cancers [3,13-17], the great success of EGFR-targeted therapy in lung cancer prompted us to put emphasis on the EGFR pathway in this analysis, with the hypothesis that the EGFR signaling pathway is a potential therapeutic target and that blocking both IGF1R and EGFR simultaneously in MPNST might result in a synergistic antitumor effect. Here, IGF1R is linked to malignant peripheral nerve sheath tumor.